Three teams at the Crick have been some of the first researchers to test Google DeepMind’s new protein design system, AlphaProteo. AlphaProteo uses artificial intelligence to design proteins that bind to target molecules and could help to create new drugs and biosensors. The teams at the Crick validated protein binders designed and tested by Google DeepMind, confirming that they not only show the binding interactions predicted by AlphaDesign, but that they meet or exceed the biological function that they were designed to do. Find out more about AlphaProteo and its potential applications in Google DeepMind's blog post ⤵️
Introducing AlphaProteo: an AI system for designing novel proteins that bind more successfully to target molecules. 🧬 This research could help deepen our understanding of fundamental biology. Here’s how: 🔵 Protein binders are essential tools in drug development and biotech. They’ve already demonstrated potential in binding cancer cells, blocking viral infections and more. 🔵 AlphaProteo managed to generate candidates with strong binding to 7️⃣ diverse proteins related to infection, cancer, inflammation, and autoimmune disease. 🔵 AI for protein design has great potential - but more work is needed. We’re improving AlphaProteo’s success rate and will continue working with scientists to develop a responsible offering for the community. Find out more ↓https://dpmd.ai/4geFM0L